在帕金森病的 Salience 网络和认知障碍
Brooke E Yeager1, Hunter P Twedt1, Joel Bruss1,2
1Department of Neurology, Carver College of Medicine, University of Iowa, Iowa City, 52242, USA.
medRxiv : the preprint server for health sciences
|October 24, 2023
概括
帕金森病 (PD) 的认知障碍与大脑网络连接的改变有关. 具体来说,减少的前端双双体网络连接和突出网络相互作用与PD患者的认知功能得分较低相关.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 认知科学 认知科学
背景情况:
- 帕金森病 (PD) 呈现出运动和认知缺陷.
- 大脑网络功能障碍与PD有关,但认知障碍背后的网络需要进一步调查.
研究的目的:
- 为了研究与帕金森病中认知障碍相关的脑网络变化.
- 测试突出网络 (SN) 参与PD认知缺陷的假设.
主要方法:
- 利用了来自帕金森氏症进展标记计划 (PPMI) 的静止状态功能磁共振成像 (rs-fMRI) 数据.
- 检查了前端对象网络 (FPN) 内的连接性,以及突出网络 (SN),基底腺网络 (BGN) 和默认模式网络 (DMN) 之间的连接性.
- 与82名PD患者的蒙特利尔认知评估 (MoCA) 成绩相关联的网络连接.
主要成果:
- 较低的FPN网络内部连接与较低的MoCA分数有显著的关联.
- 在SN和BGN之间,以及在SN和DMN之间,网络间连接性减少也与较低的MoCA分数相关.
结论:
- 这些发现支持突出网络在帕金森病中观察到的认知障碍中的作用.
- 确定了与PD认知功能障碍相关的特定网络连接改变 (FPN,SN,BGN,DMN),提供了新的见解.
相关概念视频
Parkinson's Disease: Overview
567
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
567
Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
Parkinson's Disease: Treatment
281
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
281
Negative and Cognitive Symptoms of Schizophrenia
50
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
50
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
131
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
131


